- Schomig A, Neumann F-J, Kastrati A et al. A randomised comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. N Engl J Med 1996; 334: 1084-1089.
- Ticlopidine hydrochloride; clinical information data. Sanofi Winthrop, Guildford, Surrey, UK, 1997.
- Mass WK, Easton JD, Adams HP Jr et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501-507.
- Gent M, Blakely J, Easton JD et al. The Canadian American ticlopidine study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215-1220.
- Goods CM, Al-Shaibi KF, Liu MW et al. Comparison of aspirin alone versus aspirin plus ticlopidine after coronary artery stenting. Am J Cardiol 1996; 78: 1042-1044.
- Albeiro R, Hall P, ltoh A et al. Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation. Comparison of aspirin alone versus combined aspirin and ticlopidine therapy. Circulation 1997; 95: 1145-1156.
- Hall P, Nakamura S, Maiello I. et al. A randomised comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 1996; 93: 215-222.
- Colombo A, Hall P, Nakamura S et al. lntracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995; 91: 1676-1688.
- Leon MB, Baim DS, Popma JJ et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998; 339: 1665-1671.
- Berger PB, Grill DE, Melby SJ, Bell MR, Holmes DJ Jr. Can ticlopidine be safely discontinued two weeks after coronary stent placement? J Am Coll Cardiol 1998; 31(suppl): 458A (abstr).
- Berger PB, Bell MR, Grill DE, Melby S, Holmes DJ Jr. Frequency of adverse clinical events in the 12 months following successful intracoronary stent placement in patients treated with aspirin and ticlopidine (without warfarin). Am J Cardiol 1998; 81: 713-718.
- Ellis SG, Roubin GS, King SB III et al. Angiographie and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation 1988; 72: 372-379.
- de Feyter PJ, Ruygrok PN. Coronary intervention: risk stratification and management of abrupt coronary occlusion. Eur Heart J 1995; 16 (suppl L): L97-L103.
- Schuhlen H, Hadamitzky M, Walter H, UIm K, Schomig A. Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary PalmazSchatz stent placement. Analysis of the prospective risk stratification protocol in the intracoronary stenting and antithrombotic regimen (ISAR) trial. Circulation 1997; 95: 2015-2021.
- The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein lIb/IlIa receptor in high-risk coronary angioplasty, the EPIC investigation. N Engl J Med 1994; 330: 956-961.
- The EPILOG Investigators. Platelet glycoprotein Ilb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-1696.
- The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina. Lancet 1997; 349: 435 (correction Lancet 1997; 350: 744).
- The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-contiOlled trial to assess safety of coronary stenting with the use of platelet glycoprotein Ilb/IIIa blockade. Lancet 1998; 352: 87-92.
- The CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
International Journal of Cardiovascular Interventions
Volume 3, 2000 - Issue 1